Discovery Biology, Global Research and Development, St. Louis Laboratories, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA.
Cytokine. 2010 Dec;52(3):215-20. doi: 10.1016/j.cyto.2010.08.005. Epub 2010 Sep 9.
The aim of this study is to investigate if macrophage-colony stimulating factor (M-CSF) or interleukin-34 (IL-34) induces cytokines or chemokines using human whole blood (HWB) and if an M-CSF- or IL-34-induced cytokine or chemokine production from HWB is inhibited by soluble M-CSF receptor or c-FMS kinase inhibitors. Among eight cytokines or growth factors tested, only IL-6 level was increased by up to 6-fold by M-CSF or IL-34 in HWB. In contrast, chemokine levels (IP-10/CXCL10, IL-8/CXCL8, and MCP-1/CCL2) were dramatically increased by M-CSF or IL-34 in HWB while exhibiting a large variation among donors. Variability of the MCP-1 signal induced by M-CSF or IL-34 was relatively less among donors compared to the IP-10 and IL-8 signals. The elevation of these chemokine levels was significantly decreased by soluble M-CSF receptor, indicating the elevation of these chemokines was mediated by M-CSF or IL-34. Furthermore, GW2580, a c-FMS kinase inhibitor, inhibited the induction of MCP-1 by M-CSF or IL-34 in a concentration dependent manner. These indicate MCP-1 is the most appropriate chemokine target for a chemokine release assay to evaluate the potency of c-FMS kinase inhibitors and MCP-1 release assay using HWB would be useful, relevant tool for translational pharmacology of c-FMS kinase inhibitors.
本研究旨在探讨巨噬细胞集落刺激因子(M-CSF)或白细胞介素 34(IL-34)是否会诱导人全血(HWB)中的细胞因子或趋化因子产生,以及可溶性 M-CSF 受体或 c-FMS 激酶抑制剂是否会抑制 M-CSF 或 IL-34 诱导的 HWB 中细胞因子或趋化因子的产生。在测试的八种细胞因子或生长因子中,只有 M-CSF 或 IL-34 可将 HWB 中的 IL-6 水平提高至 6 倍。相比之下,趋化因子水平(IP-10/CXCL10、IL-8/CXCL8 和 MCP-1/CCL2)在 HWB 中被 M-CSF 或 IL-34 显著增加,而在供体之间存在较大差异。与 IP-10 和 IL-8 信号相比,M-CSF 或 IL-34 诱导的 MCP-1 信号的变异性在供体之间相对较小。可溶性 M-CSF 受体显著降低了这些趋化因子水平的升高,表明这些趋化因子的升高是由 M-CSF 或 IL-34 介导的。此外,c-FMS 激酶抑制剂 GW2580 以浓度依赖的方式抑制了 M-CSF 或 IL-34 诱导的 MCP-1 产生。这些表明 MCP-1 是评估 c-FMS 激酶抑制剂效力的趋化因子释放测定中最合适的趋化因子靶标,并且使用 HWB 的 MCP-1 释放测定将是评估 c-FMS 激酶抑制剂的转化药理学的有用、相关工具。